We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




PerkinElmer Acquires Indian IVD Firm Tulip Diagnostics

By LabMedica International staff writers
Posted on 17 Jan 2017
PerkinElmer, Inc., which offers products, services and solutions for the diagnostics, research, environmental, industrial and laboratory services market, has entered into a definitive agreement to acquire Tulip Diagnostics Private Ltd., one of India’s largest domestic providers of in-vitro diagnostic reagents, kits and instruments.

PerkinElmer offers a global diagnostics portfolio focused on: reproductive health, infectious disease screening and genomics offerings for oncology and other molecular tests through its wide range of instruments, reagents, assay platforms and software offerings. More...
The company also offers instruments and services to its customers in India where it even has a laboratory for providing access to technologies that screen for and help diagnose prenatal and neonatal conditions.

Tulip’s solutions include products for the prevention, screening and diagnosis of infectious diseases such as malaria, HIV and hepatitis, and it has two manufacturing facilities located in India.

“In-vitro diagnostics is one of the fastest growing vertical segments in India, and Tulip provides the key enablers for PerkinElmer to broaden our infectious disease screening menu and capabilities for customers throughout the region,” said Jayashree Thacker, President, PerkinElmer India. “The acquisition underscores our commitment to bringing advanced healthcare innovations into India, while continuing to further expand our footprint in the country.”

“Combining our product portfolio and channel access in India with PerkinElmer’s established position as a global diagnostics provider enables us to work closely with customers in India to bring the latest infectious disease technologies to them at an affordable cost,” said Deepak Tripathi, Director and Co-founder of Tulip.


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Electrolyte Analyzer
BKE-B
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The blood-based assay captures circulating chromatin, cell-free DNA fragments that are largely inaccessible through standard laboratory methods (image credit: Shuttertstock)

Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response

Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read more

Immunology

view channel
Image: New research shows that autoimmunity drives debilitating long COVID symptoms in a subset of patients (Image credit: Shutterstock)

Study Points to Autoimmune Pathway Behind Long COVID Symptoms

Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.